AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
05 Dec 2019 07:00 AM
RNS
Lynparza approved in China for 1L BRCAm ovarian
03 Dec 2019 07:00 AM
RNS
AstraZeneca divests Seroquel rights: US and Canada
02 Dec 2019 03:00 PM
RNS
Block listing Interim Review
02 Dec 2019 03:00 PM
RNS
Total Voting Rights
29 Nov 2019 07:00 AM
RNS
Imfinzi granted FDA Priority Review for SCLC
21 Nov 2019 06:15 PM
RNS
Calquence approved in CLL in the US
15 Nov 2019 07:00 AM
RNS
Qtrilmet approved in the EU for treatment of T2D
14 Nov 2019 07:00 AM
RNS
FDA accepts regulatory submission for selumetinib
12 Nov 2019 07:00 AM
RNS
Anifrolumab demonstrated superiority in TULIP 2
11 Nov 2019 07:00 AM
RNS
Roxadustat pooled analyses: no increased CV risk
08 Nov 2019 07:00 AM
RNS
Roxadustat significantly increased haemoglobin
06 Nov 2019 02:10 PM
RNS
Calquence data to show improved progression-free
01 Nov 2019 03:00 PM
RNS
Total Voting Rights
30 Oct 2019 07:00 AM
RNS
AstraZeneca divests rights to Seroquel and
28 Oct 2019 03:31 PM
RNS
Imfinzi and Imfinzi plus tremelimumab delayed
24 Oct 2019 07:00 AM
RNS
AstraZeneca year-to-date and Q3 2019 results
21 Oct 2019 07:00 AM
RNS
Farxiga approved in the US to reduce the risk of
17 Oct 2019 07:00 AM
RNS
Trastuzumab deruxtecan granted FDA Priority Review
04 Oct 2019 03:04 PM
RNS
Holding(s) in Company
04 Oct 2019 03:00 PM
RNS
Holding(s) in Company
04 Oct 2019 07:00 AM
RNS
Fasenra approved in the US for self-administration
03 Oct 2019 04:00 PM
RNS
Director Declaration
01 Oct 2019 03:00 PM
RNS
Total Voting Rights
01 Oct 2019 07:05 AM
RNS
AstraZeneca divests rights for Losec to Cheplaphar
01 Oct 2019 07:00 AM
RNS
Update on US regulatory review of PT010 in COPD
30 Sep 2019 03:30 PM
RNS
Lynparza more than doubled the time without
30 Sep 2019 07:00 AM
RNS
Lynparza improved the time women lived without
30 Sep 2019 07:00 AM
RNS
Tagrisso is the only 1st-line treatment for EGFR-
23 Sep 2019 07:00 AM
RNS
Qtrilmet recommended for approval in EU by CHMP
18 Sep 2019 07:00 AM
RNS
AstraZeneca amends collaboration with Ironwood
09 Sep 2019 08:38 AM
RNS
Imfinzi is first immunotherapy to show both
04 Sep 2019 07:11 AM
RNS
Tagrisso approved in China as a 1st-line treatment
02 Sep 2019 03:00 PM
RNS
Total Voting Rights
02 Sep 2019 07:05 AM
RNS
Brilinta reduced the risk of cardiovascular events
02 Sep 2019 07:00 AM
RNS
Detailed results from Phase III DAPA-HF trial
29 Aug 2019 07:00 AM
RNS
Anifrolumab Phase III trial meets primary endpoint
28 Aug 2019 07:05 AM
RNS
Fasenra granted US Orphan Drug Designation for
28 Aug 2019 07:00 AM
RNS
Breztri Aerosphere Phase III ETHOS trial met
22 Aug 2019 07:00 AM
RNS
Roxadustat approved in China for the treatment of
22 Aug 2019 07:00 AM
RNS
AstraZeneca agrees to buy US FDA Priority Review
21 Aug 2019 07:00 AM
RNS
Update on the Phase III NEPTUNE trial
20 Aug 2019 07:00 AM
RNS
Farxiga met primary endpoint in landmark Phase III
19 Aug 2019 07:00 AM
RNS
Directorate Change
14 Aug 2019 07:00 AM
RNS
Lynparza Phase III PAOLA-1 trial met primary endpo
14 Aug 2019 07:00 AM
RNS
Calquence granted US Breakthrough Therapy Designat
09 Aug 2019 09:28 AM
RNS
Amendment: Tagrisso significantly improves overall
09 Aug 2019 07:00 AM
RNS
Tagrisso significantly improves overall survival
07 Aug 2019 07:00 AM
RNS
Lynparza Phase III PROfound trial in HRR*
05 Aug 2019 07:00 AM
RNS
Forxiga label updated in the EU in type-2 diabetes
01 Aug 2019 03:00 PM
RNS
Total Voting Rights
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings